about
Cytotoxicity evaluation of a new set of 2-aminobenzo[de]iso-quinoline-1,3-diones3-Benzyl-6-methyl-2-sulfanylidene-2,3-di-hydroquinazolin-4(1H)-one.2-Methyl-sulfanyl-1,2,4-triazolo[1,5-a]quinazoline-5(4H)-thione.Molecular docking study and antiviral evaluation of 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives.Cytotoxicity and anti-inflammatory activity of methylsulfanyl-triazoloquinazolines.A new investigation for some steroidal derivatives as anti-Alzheimer agents.2-Eth-oxy-5-methylbis[1,2,4]triazolo[1,5-a:4',3'-c]quinazoline.Biological effects of a new set 1,2,4-triazolo[1,5-a]quinazolines on heart rate and blood pressure.N-[2,4-Dioxo-3-aza-tricyclo-[7.3.1.0(5,13)]trideca-1(13),5,7,9,11-pentaen-3-yl]thio-urea.3-Benzyl-8-meth-oxy-2-sulfanyl-idene-1,2,3,4-tetra-hydro-quinazolin-4-one2-Phen-oxy-1,2,4-triazolo[1,5-a]quinazol-in-5(4H)-one.Docking and antiherpetic activity of 2-aminobenzo[de]-isoquinoline-1,3-diones.2-Methyl-sulfanyl-1,2,4-triazolo[1,5-a]quinazolin-5(4H)-one.3-(Prop-2-en-1-yl)-2-sulfanyl-idene-1,2,3,4-tetra-hydro-quinazolin-4-one.Anti-inflammatory, analgesic, anticonvulsant and antiparkinsonian activities of some pyridine derivatives using 2,6-disubstituted isonicotinic acid hydrazides.2-Benz-yloxy-1,2,4-triazolo[1,5-a]quinazolin-5(4H)-one.Synthesis of chiral macrocyclic or linear pyridine carboxamides from pyridine-2,6-dicarbonyl dichloride as antimicrobial agents.Antimicrobial activity of newly synthesized methylsulfanyl-triazoloquinazoline derivatives.Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives.Antimicrobial Activity of Synthesized 2-Methylthiobenzo[g][1,2,4]- triazolo[1,5-a]quinazoline Derivatives.A new series of 2-alkoxy(aralkoxy)-[1,2,4]triazolo[1,5-a]quinazolin-5-ones as adenosine receptor antagonists.Investigation the antioxidant activity of benzo[g]triazoloquinazolines correlated with a DFT studyAnti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolinesSynthesis, biological activity and molecular docking of new tricyclic series as α-glucosidase inhibitorsTriazoloquinazolines as a new class of potent α-glucosidase inhibitors: in vitro evaluation and docking study
P50
Q34834584-CD2F941F-1842-4BEF-AA0C-766A8BB72604Q35808210-E02D39BF-E6F5-4203-9543-55C468455609Q36657373-440F7B89-7726-47AC-A743-2026F1F45428Q36815348-1744A508-A9FA-4432-BEFF-DE8D16EC9BEDQ39204996-B4C1BCBD-835E-4A95-B887-947F92AB59F2Q39357050-619F9D82-CB91-4FEE-83E2-911B8D6F6957Q40269242-E8988114-C213-4E22-9C76-800443D38FE2Q41893026-ED3D90E3-3569-4C83-83F9-AD08F8F892D8Q41961887-9FFAB767-F1DE-48BC-B14B-045422EBB328Q42065097-5917712F-ABA6-4A38-A19D-A9B1499F1C74Q42113686-C14EE133-1B8B-4AE2-9CCD-7290A19A41C9Q42152702-0C75E4B5-0F53-47FA-835F-C36F281D483AQ42208308-A6A46A69-C1AF-4D5F-87EC-447F7FCA2022Q42208317-6686FB6C-EA67-4094-9490-5B590383E042Q42791814-EEDEDA46-0A34-4052-8751-70F2DFE67B7AQ42858404-DC2A5BD2-8C29-4128-A632-06CAF2A3FEE9Q42874490-0F8144A3-B79F-4A1C-B485-17F20309FC01Q44611866-C9E97481-30C8-4CCC-BBDB-079063B2DD49Q46532048-63EE8BF0-2E9B-4DE6-AF0C-CC30B8234F07Q46554281-74EB3F0C-F27D-47F8-9E7E-E4B337F75658Q51767506-E219DE34-A66D-495D-B8D0-0E174BAE7ED3Q91131347-3C5211A1-CE77-4CFF-BF25-6D3CEFC4B415Q91759185-14529F99-F407-47FA-9741-1A216FE21FC4Q92437839-530BF8D0-4F2B-4E78-B7F5-DBE939BFEE14Q92616628-96C1E740-6655-4847-838D-6423BD3D36FE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Rashad A Al-Salahi
@en
Rashad A Al-Salahi
@nl
type
label
Rashad A Al-Salahi
@en
Rashad A Al-Salahi
@nl
prefLabel
Rashad A Al-Salahi
@en
Rashad A Al-Salahi
@nl
P31
P496
0000-0003-1747-2736